Tekin Hande GazeteciLevent Ertürk2023-03-222023-03-2220221022386Xhttps://doi.org/10.29271/jcpsp.2022.05.671https://hdl.handle.net/20.500.14034/896Friedreich's ataxia (FA) is a rare, progressive, and degenerative hereditary disorder caused by a deficiency of frataxin protein. This disease is characterised by severe neurological dysfunction and life-threatening cardiomyopathy. Various drugs are used to slow down / stop the neurodegenerative progress. However, recent clinical trials and animal experiments demonstrate that interferon- gamma (IFN-?) treatment might improve signs of FA as well. A 9-year-old girl was admitted to our hospital with gait instability, mild dysarthria, and sensorimotor polyneuropathy. Her genetic examination was consistent with FA. IFN-? treatment was started 3 times a week. The treatment was evaluated by physical examination and side effects assessment. Friedreich Ataxia Rating Scale (FARS), 9- hole peg test (9HPT), and time of 25-foot walk (T25FW) were measured. Ataxia and cerebellar findings improved within 9 months. Although clinical neurological improvement was achieved, there was no improvement in cardiomyopathy. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.eninfo:eu-repo/semantics/openAccessCardiomyopathyChildrenFARSFriedreich ataxiaInterferon-gammagamma1b interferonidebenonemetoprololubiquinonegamma interferonareflexiaarm movementArticlecase reportchildclinical articleconvalescencedysarthriadysmetriaechocardiographyelectrocardiogramelectromyographyfemalefinger to finger testfinger to nose testflu like syndromefollow upFriedreich ataxiaFriedreich Ataxia Rating Scalegenetic analysishammertoeheart left ventricle hypertrophyhumanhypertrophic cardiomyopathymotor dysfunctionmotor function testnerve conduction velocityneurologic disease assessmentneurologic gait disordernine hole peg testpes cavusphysical examinationphysiotherapyschool childsensorimotor neuropathywalk testcardiomyopathycomplicationFriedreich ataxiawalkingCardiomyopathiesFemaleFriedreich AtaxiaHumansInterferon-gammaWalkingArticle10.29271/jcpsp.2022.05.6713256716732-s2.0-8513063165235546709Q3